Colorectal Cancer
We recommend
Benefit of Adding Panitumumab to Maintenance Therapy in mCRC with Non-mutated RAS Oncogene
PANAMA was the first randomized study evaluating the addition of an anti-EGFR antibody to maintenance therapy with fluorouracil and folic acid (FU/FA) in patients with previously untreated metastatic colorectal cancer (mCRC) with a non-mutated (wt − wild-type) RAS oncogene. The results suggest that upon achieving disease control after initial treatment with FOLFOX + panitumumab, the combination of panitumumab with FU/FA might be the most suitable for maintenance therapy.
Combination of Targeted Therapy with Chemo in 1st Line in Patients with Left-Sided wtRAS mCRC
The preferred targeted therapy added to the combination with standard chemotherapy (CHT) for…
Early Tumor Regression as a Marker of Overall Survival in First-Line Treatment of mCRC
In the treatment of metastatic colorectal cancer (mCRC), prognostic factors besides overall…
Articles on this topic
Maintenance Therapy After Oxaliplatin Discontinuation Based on Panitumumab
Panitumumab is an approved therapy for metastatic colorectal cancer without RAS oncogene…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Interesting links
Most read on this topic
- Successful Resection of a Rectosigmoid Tumor After Long-term Induction Biochemotherapy – A Case Report
- INTERACTIVE CASE STUDY of a patient with mCRC treated long-term with various modalities
- Biochemotherapy of Aggressive Rectal Carcinoma – A Case Study from the Czech Republic
- Combination of Targeted Therapy with Chemo in 1st Line in Patients with Left-Sided wtRAS mCRC
- Early Tumor Regression as a Marker of Overall Survival in First-Line Treatment of mCRC
- Impact of Body Mass Index on Survival and Treatment Outcomes of Metastatic Colorectal Cancer
Journal on this topic
Related topic
Interesting links